Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$47.03

0.32 (0.69%)

07:02
10/03/16
10/03
07:02
10/03/16
07:02

Alkermes announces initiation of ALKS 3831 study for schizophrenia treatment

Alkermes announced the initiation of a clinical study designed to evaluate the metabolic profile of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate, compared to olanzapine, an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain. The randomized, double-blind, parallel-group study will characterize metabolic parameters, including insulin sensitivity and lipid metabolism, in response to treatment with ALKS 3831 and olanzapine. This exploratory metabolic study in healthy subjects is a supportive study in the ENLIGHTEN pivotal program of ALKS 3831 for the treatment of schizophrenia. The two key phase 3 studies, ENLIGHTEN-1 and ENLIGHTEN-2, have been enrolling patients since December 2015 and February 2016, respectively. The objective of the newly-initiated metabolic study is to more fully characterize the comparative metabolic effects of ALKS 3831 and olanzapine, in order to understand the potential metabolic benefits of ALKS 3831 and to build on the findings from previously conducted preclinical and clinical studies that suggest treatment with ALKS 3831 is associated with less weight gain compared to olanzapine. ALKS 3831 is designed to provide patients with the strong efficacy of olanzapine with favorable weight and metabolic properties. The phase 1 metabolic study will assess the effects of ALKS 3831 on whole body insulin sensitivity, lipid metabolism and other important metabolic parameters compared to olanzapine. Approximately 50 healthy subjects will be randomized to receive ALKS 3831, olanzapine or placebo for 21 days. Results from the study are expected in the first half of 2017.

  • 06

    Nov

ALKS Alkermes
$47.03

0.32 (0.69%)

07/29/16
FBCO
07/29/16
NO CHANGE
Target $52
FBCO
Outperform
Alkermes quarter raised some questions, says Credit Suisse
Credit Suisse analyst Vamil Divan says Alkermes' Q2 results, while solid overall, raised some questions. The stock came under pressure yesterday given some questions around net pricing for Vivitrol as well development timelines around ALKS 8700, Divan tells investors in a post-earnings research note. Vivitrol sales slightly missed what some investors were hoping for since an increased percentage of volume came at lower net prices from Medicaid customers, the analyst contends. Divan remains bullish on the overall story and views the stock's risk/reward as attractive ahead of the FORWARD-5 data by year-end. He raised his price target for the shares to $52 from $45 and keeps an Outperform rating on Alkermes.
07/29/16
COWN
07/29/16
NO CHANGE
Target $60
COWN
Outperform
Alkermes weakness a buying opportunity, says Cowen
Cowen said the weakness in Alkermes is a buying opportunity as they believe the magnitude, sustainability, and impact of Vivitrol's growth is being meaningfully underestimated by the Street. Cowen reiterated its Outperform rating and $60 price target on Alkermes shares.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $53
SBSH
Neutral
Alkermes price target raised to $53 from $44 at Citi
Citi analyst Liav Abraham raised her price target for Alkermes to $53 after the company hosted an investor event to overview the various aspects of Vivitrol. Alkermes' execution on a "unique commercial model," which targets the differing opioid addiction population needs on a state-by-state basis, is likely to drive robust volume growth going forward, particularly in the Medicaid patient population, Abraham tells investors in a research note. The analyst raised her estimates for Vivitrol but remains cautious on the FORWARD-5 data for ALKS 5461 due out in Q4. As such, Abraham keeps a Neutral rating on Alkermes.
09/27/16
JEFF
09/27/16
NO CHANGE
Target $62
JEFF
Buy
Alkermes sees significant room for Vivitrol upside, says Jefferies
Alkermes yesterday at its Vivitrol-focused event highlighted that the opioid treatment is still in the early stages of growth, Jefferies analyst Biren Amin tells investors in a research note. The company estimates that Vivitrol is currently capturing only 2% average market share and believes room for upside is significant, the analyst writes. He keeps a Buy rating on Alkermes with a $62 price target.

TODAY'S FREE FLY STORIES

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Earnings
Teleflex reports Q4 adjusted EPS $2.13, consensus $2.09 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

DORM

Dorman Products

$77.94

5.68 (7.86%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Downgrade
Dorman Products rating change  »

Dorman Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$85.73

-0.95 (-1.10%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Earnings
Zebra Technologies reports Q4 EPS $1.93, consensus $1.73 »

Reports Q4 revenue $942M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

WAAS

AquaVenture

$18.01

0.69 (3.98%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Upgrade
AquaVenture rating change  »

AquaVenture upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:32
02/23/17
02/23
06:32
02/23/17
06:32
Hot Stocks
Breaking Hot Stocks news story on SAGE Therapeutics »

SAGE Therapeutics sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Earnings
Breaking Earnings news story on SAGE Therapeutics »

SAGE Therapeutics reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Recommendations
Labarge analyst commentary  »

L Brands selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GE

General Electric

$30.09

-0.19 (-0.63%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Periodicals
Suez in the running for General Electric's water unit, Reuters reports »

France's Suez is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

DLHC

DLH Holdings Corp.

$5.27

-0.08 (-1.50%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Initiation
DLH Holdings Corp. initiated  »

DLH Holdings Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CM

CIBC

$89.90

0.44 (0.49%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Earnings
CIBC reports Q1 adjusted EPS C$2.89, consensus C$1.96 »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMRE

Global Medical REIT

$8.48

0.06 (0.71%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Initiation
Global Medical REIT initiated  »

Global Medical REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:25
02/23/17
02/23
06:25
02/23/17
06:25
Hot Stocks
Teleflex CEO Benson Smith retiring at end of 2017, succeeded by COO Liam Kelly »

Teleflex CEO Benson Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

MBLY

Mobileye

$47.42

1.3 (2.82%)

06:22
02/23/17
02/23
06:22
02/23/17
06:22
Recommendations
Mobileye analyst commentary  »

Mobileye price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:20
02/23/17
02/23
06:20
02/23/17
06:20
Hot Stocks
Carter's raises quarterly dividend 12% to 37c per share »

For payment on March 24…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:19
02/23/17
02/23
06:19
02/23/17
06:19
Earnings
Carter's sees FY17 adjusted EPS growth 8%-10%, consensus $5.52 »

For fiscal 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:18
02/23/17
02/23
06:18
02/23/17
06:18
Earnings
Carter's sees Q1 adjusted EPS 80c-85c, consensus $1.14 »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NVCR

Novocure

$7.15

-0.15 (-2.05%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Hot Stocks
Novocure Chief Commercial Officer Peter Melnyk departing »

Novocure's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 02

    Mar

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Periodicals
Credit Suisse allocates $600M to expand Saudi Arabia business, Bloomberg says »

Credit Suisse is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OUT

OUTFRONT Media

$26.89

-0.44 (-1.61%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Downgrade
OUTFRONT Media rating change  »

OUTFRONT Media downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Breaking Hot Stocks news story on Carter's »

Carter's raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Energy Focus sees Q1 restructuring charges of $1.1M »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Earnings
Carter's reports Q4 adjusted EPS $1.79, consensus $1.67 »

Reports Q4 revenue $934M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CMVT

Comverse

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Periodicals
Former Comverse CEO faces sentencing in fraud case, Reuters reports »

Jacob "Kobi"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Recommendations
Energy Focus analyst commentary  »

Energy Focus reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

, MON

Monsanto

$111.38

0.81 (0.73%)

06:13
02/23/17
02/23
06:13
02/23/17
06:13
Periodicals
Bayer looks to raise $19B in equity to fund proposed Monsanto deal, WSJ reports »

Bayer (BAYRY) is looking…

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

MON

Monsanto

$111.38

0.81 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

  • 01

    Apr

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.